Canadian regulators wade into Alzheimer’s drug controversy

By Noel Courage and Iris Cheung (September 14, 2022, 1:29 PM EDT) -- In June 2022, neuroscience firm Biogen withdrew its Canadian drug submission for approval of aducanumab, which is a monoclonal antibody drug for the treatment of Alzheimer’s disease (AD). The company’s statement said, “… based on the review to date, the agency [Health Canada] indicated that the data provided would not be sufficient to support a marketing authorization in Canada.” Biogen’s withdrawal of the drug submission did not come as a surprise, since the drug application was withdrawn in Europe....